Get started
Author

Karin Havenith

Observed names: Havenith, K, K Havenith, K. Havenith, KARIN HAVENITH, Karin E. Havenith, Karin E.G. Havenith, Karin EG. Havenith
ORCID: 0000-0002-0610-4228
Observed ORCID: 0000-0002-0610-4228
OpenAlex ID: A5068778166
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
2021 · Paolo F Caimi, Weiyun Ai, et al. · The Lancet Oncology · 442
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
2020 · Mehdi Hamadani, John Radford, et al. · Blood · 178
PDF
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
2019 · Brad S. Kahl, Mehdi Hamadani, et al. · Clinical Cancer Research · 105
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
2021 · Mehdi Hamadani, Graham P Collins, et al. · The Lancet Haematology · 86
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
2020 · Francesca Zammarchi, Karin Havenith, et al. · Journal for ImmunoTherapy of Cancer · 82
PDF
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
2020 · Nitin Jain, Wendy Stock, et al. · Blood Advances · 56
PDF
Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D–Dependent Kinases
1997 · Masashi Adachi, Martine F. Roussel, et al. · Blood · 51
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
2020 · Aaron D. Goldberg, Ehab Atallah, et al. · Leukemia Research · 41
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant
2024 · Jenny Yeung, Aiyin Liao, et al. · Molecular Therapy · 23
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma
2024 · Amber K. Hamilton, Alexander B. Radaoui, et al. · Cancer Cell · 19
ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers
2016 · F. Zammarchi, S. Chivers, et al. · European Journal of Cancer · 16
A Subset of Splenic Macrophages Process and Present Native Antigen to Naive Antigen-Specific CD4+T-Cells from Mice Transgenic for an αβ T-Cell Receptor
1995 · DAVID ASKEW, JANET GATEWOOD, et al. · Cellular Immunology · 15
hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.
2016 · Francesca Zammarchi, Simon Corbett, et al. · Blood · 13
ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
2024 · Francesca Zammarchi, Karin E. Havenith, et al. · Molecular Cancer Therapeutics · 12
PDF
In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
2023 · Paolo F. Caimi, Mehdi Hamadani, et al. · eJHaem · 12
PDF
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
2025 · Alex F. Herrera, Stephen M. Ansell, et al. · Blood Advances · 10
PDF
Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
2018 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 10
Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies
2015 · Francesca Zammarchi, David G. Williams, et al. · Blood · 10
Interim Data From the First Clinical Study of Adct‐301, a Novel Pyrrolobenzodiazapine‐based Antibody Drug Conjugate, in Relapsed/refractory Hodgkin/non‐hodgkin Lymphoma
2017 · S.M. Horwitz, M.A. Fanale, et al. · Hematological Oncology · 9
PDF
CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
2022 · Paolo F. Caimi, Mehdi Hamadani, et al. · Blood · 8
Clinical Activity of Loncastuximab Tesirine Plus Ibrutinib in Non‐hodgkin Lymphoma: Updated Lotis 3 Phase 1 Results
2021 · J Depaus, N Wagner‐Johnston, et al. · Hematological Oncology · 8
PDF
Abstract CT059: Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas
2024 · Brian Andrew Van Tine, Christopher T. Chen, et al. · Cancer Research · 7
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma
2022 · Marie Toukam, Jens Wuerthner, et al. · Cancer Chemotherapy and Pharmacology · 7
First Clinical Results of Adct‐402, a Novel Pyrrolobenzodiazepine‐based Antibody Drug Conjugate (adc), in Relapsed/refractory B‐cell Lineage Nhl
2017 · B. Kahl, M. Hamadani, et al. · Hematological Oncology · 7
PDF
Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
2018 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 6
Works count: 97
Citation count: 1,282
H-index: 13
I10-index: 18
Year
Topic
Type